Reply to Can quantified pathologic response assessed as residual tumor burden be a promising staging system for patients with rectal cancer treated with chemoradiation followed by surgery?

Affiliations

Free article

Comment

Dipen M Maru et al. Cancer. 2014.

Free article

. 2014 Apr 15;120(8):1282.

doi: 10.1002/cncr.28559. Epub 2014 Jan 28.

¹ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

No abstract available

Comment on

Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy.
Agarwal A, Chang GJ, Hu CY, Taggart M, Rashid A, Park IJ, You YN, Das P, Krishnan S, Crane CH, Rodriguez-Bigas M, Skibber J, Ellis L, Eng C, Kopetz S, Maru DM. Agarwal A, et al. Cancer. 2013 Dec 15;119(24):4231-41. doi: 10.1002/cncr.28331. Epub 2013 Oct 1. Cancer. 2013. PMID: 24089344 Free PMC article.
Can quantified pathologic response assessed as residual tumor burden be a promising staging system for patients with rectal cancer treated with chemoradiation followed by surgery?
You KY, Gao YH. You KY, et al. Cancer. 2014 Apr 15;120(8):1281-2. doi: 10.1002/cncr.28560. Epub 2014 Jan 28. Cancer. 2014. PMID: 24474633 No abstract available.